-
Mashup Score: 19Imetelstat Produces RBC Transfusion Independence in Lower-Risk Myelodysplastic Syndromes | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The competitive telomerase inhibitor imetelstat produced prolonged independence from red blood cell (RBC) transfusions in a considerable number of patients with lower-risk myelodysplastic syndromes (MDS) who were ineligible for, had relapsed on, or been refractory to erythropoiesis-stimulating agents (ESA), according to new phase III findings published in The Lancet. The results from the IMerge trial point to the prospect of a
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 63
There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet
Phase III findings in @TheLancet found that #imetelstat produced prolonged independence from RBC transfusions in a considerable number of patients with lower-risk #MDS who were ineligible for, had relapsed on, or been refractory to ESAs. https://t.co/BjhFeq1Lk1